Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases

Frontiers in Medicinal Chemistry

Volumn 4, Issue 1, 2009, Pages 347-370

  Hirai, Hiroshi ^a   Kawanishi, Nobuhiko ^a   Iwasawa, Yoshikazu ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CDK inhibitor; CDK2; CDK4; CDK6; Cyclin dependent kinase

Indexed keywords

EID: 79959763054     PISSN: 15672042     EISSN: 18755763     Source Type: Book Series    
DOI: None     Document Type: Article

References (116)

1. Sherr, C.J. Cancer cell cycles. Science, 1996, 274, 1672-1677.
2. Sherr, C.J. The Pezcoller lecture: cancer cell cycles revised. Cancer Res., 2000, 60, 3689-3695.
3. Pines, J. Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res., 1995, 66, 181-212.
4. Sherr, C.J.; Roberts, J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 1999, 13, 1501-1512.
5. Pavletich, N.P. Mechanism of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators, and CIP and INK4 inhibitors. J. Mol. Biol., 1999, 287, 821-828.
6. Koepp, D.M.; Haper, J.W.; Elledge, S.J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell, 1999, 97, 431-434.
7. Dyson, N. The regulation of E2F by pRb-family proteins. Genes Dev., 1998, 12, 2245-2262.
8. Zheng, L.; Lee, W.H. The retinoblastoma gene: a prototypic and multifunctional tumor suppressor. Exp. Cell Res., 2001, 264, 2-18.
9. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharm. Sci., 2002, 23, 417-425.
10. Kobor, M.S.; Greenblatt, J. Regulation of transcription elongation by phosphorylation. Biochim. Biophys. Acta, 2002, 1577, 261-275.
11. Oelgeschlager, T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell. Physiol., 2002, 190, 160-169.
12. Falco, G.D.; Giordan, A. CDK9 (PITALRE): a multifunctional cdc2-related kinase. J. Cell Physiol., 1998, 177, 501-506.
13. Price, D.H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 2000, 20, 2629-2634.
14. Dhavan, R.; Tsai, L-H. A decade of CDK5. Nat. Rev. Mol. Cell. Biol., 2001, 2, 749-759.
15. Lilja, L.; Yang, S.; Webb, D.; Juntti-Berggren, L.; Berggren, P.; Bark, C. Cyclin-dependent kinase 5 promotes insulin exocytosis. J. Biol. Chem., 2001, 276, 34199-34205.
16. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancers. Adv. Cancer Res., 1996, 68, 67-108.
17. Fisher, P.M.; Gianella-Borradori, A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs, 2003, 12, 955-970.
18. Senderowicz, A.M.; Sausville, E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst., 2000, 92, 376-387.
19. Sedlacek, H.H. Mechanism of action of flavopiridol. Crit. Rev. Oncol. Hematol., 2001, 38, 139-170.
20. Whittaker, S.R.; Walton, M.I.; Garrett, M.D.; Workman, P. The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) inhibits Retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res., 2004, 64, 262-272.
21. Hamdouchi, C.; Keyser, H.; Collins, E.; Jaramillo, C.; De Diego, J-E.; Spencer, C.D.; Dempsey, J.A.; Anderson, B.D.; Leggett, T.; Stamm, N.B.; Schultz, R.M.; Watkins, S.A.; Cocke, K.; Lemke, S.; Burke, T.F.; Beckmann, R.P.; Dixon, J.T.; Gurganus, T.M.; Rankl, N.B.; Houck, K.A.; Zhang, F.; Vieth, M.; Espinosa, J.; Timm, D.E.; Campbell, R.M.; Patel, B.K.R.; Brooks, H.B. The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol. Cancer Ther., 2004, 3, 1-9.
22. Lane, M.E.; Yu, B.; Rice, A.; Lipson, K.E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R.G.; Wadler, S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res., 2001, 61, 6170-6177.
23. Misra, R.N.; Xiao, H.; Kim, K.S.; Lu, S.; Han, W-C.; Barbosa, S.A.; Hunt, J.T.; Rawlins, D.B.; Shan, W.; Ahmed, S.Z.; Qian, L.; Chen, B.; Zhao, R.; Bednarz, M.S.; Kellar, K.A.; Mulheron, J.G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S.A.; Sack, J.S.; Tokarski, J.S.; Pavletich, N.P.; Lee, F.Y.F.; Webster, K. R.; Kimball, S.D. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclindependent kinase 2. N-[5-5-(1,1-dimethylethyl)-2-oxazolul]methyl]thiol]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem., 2004, 47, 1719-1728.
24. Chen, Y.P.; Sharma, S.K.; Ramsey, T.M.; Jiang, L.; Martin, M.S.; Baker, K.; Adams, P.; Bair, K.W.; Kaelin, W.G. Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA., 1999, 96, 4325-4329.
25. Mendoza, N.; Fong, S.; Marsters, J.; Koeppen, H.; Schwall, R.; Wickramasinghe, D. Selective cyclindependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res., 2003, 63, 1020-1024.
26. Krek, W.; Ewen, M.E.; Shirodkar, S.; Arany, Z.; Kaelin, W.G. Jr.; Livingston, D.M. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell, 1994, 78, 161-172.
27. Dynlacht, B.D.; Flores, O.; Lees, J.A.; Harlow, E. Differential regulation of E2F transactivation by cyclincdk2 complexes. Genes Dev., 1994, 8, 1772-1786.
28. Xu, M.; Sheppard, K.A.; Peng, C.Y.; Yee, A.S.; Piwinica-Worms, H. Cyclin A/Cdk2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol., 1994, 14, 8420-8431.
29. Kitagawa, M.; Higashi, H.; Suzuki-Takahashi, I.; Segawa, K.; Hanks, S.K.; Taya, Y.; Nishimura, S.; Okuyama, A. Phosphorylation of E2F-1 by Cyclin A-Cdk2. Oncogene, 1995, 10, 229-236.
30. Matranga, C.B.; Shapiro, G.I. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res., 2002, 62, 1707-1717.
31. Ma, Y.; Cress, W.D.; Haura, E.B. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F-1 and repression of Mcl-1. Mol. Cancer Ther., 2003, 2, 73-81.
32. Jiang, J.; Matranga, C.B.; Cai, D.; Latham, V.M. Jr.; Zhang, X.; Lowell, A.M.; Martelli, F.; Shapiro, G.I. Flavopiridol-induced apoptosis during S-phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res., 2003, 63, 7410-7422.
33. Thomas, A.; Culshaw, J.; Byth, K.; Oakes, S. The discovery of 4-amino-2-anilino-5-cyanopyrimdines as selective CDK inhibitors and potential orally active anti-tumor agents. EORTC-NCI-AACR International Conference on "Molecular Targets and Cancer Therapeutics", Boston, MA, 2003, Poster, C63.
34. th Annu Mtg. Proc. Am. Assoc. Cancer Res., Orlando, FL, 2004, Abstr., 836.
35. th Annu. Mtg. Proc. Am. Assoc. Cancer Res., Orlando, FL, 2004, Abstr., 832.
36. Byth, K.F.; Cooper, N.; Culshaw, J.D.; Heaton, D.W.; Oakes, S.E.; Minshull, C.A.; Norman, R.A.; Pauptit, R.A.; Tucker, J.A.; Breed, J.; Pannifer, A.; Rowsell, S.; Stanway, J.J.; Valentine, A.L.; Thomas, A.P. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 2249-2252.
37. Byth, K.F.; Culshaw, J.D.; Green, S.; Oakes, S.E.; Thomas, A.P. Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 2245-2248.
38. rd Natl. Mtg. Am. Chem. Soc., Orlando, FA, 2002, Abst MEDI 251.
39. Misra, R.N.; Xiao, H.; Williams, D.K.; Kim, K.S.; Lu, S.; Keller, K.A.; Mulheron, J. G.; Batorsky, R.; Tokarski, J.S.; Sack, J.S.; Kimball, S.D.; Lee, F.Y.; Webster, K.R. Synthesis and biological activity of Naryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett., 2004, 14, 2973-2977.
40. Sausville, E.A. Cyclin-dependent kinase modulators studied at the NCI: Pre-clinical and clinical studies. Curr. Med. Chem. Anti-Cancer Agents, 2003, 3, 47-56.
41. Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status. Expert Opin. Investig. Drugs, 2000, 9, 2903-11.
42. Zhai, S.; Senderowicz, A.M.; Sausville, E.A.; Figgs, W.D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother, 2002, 36, 905-911.
43. Tan, A.R., Swain, S.M. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin. Oncol., 2002, 29, 77-85.
44. th Annu. Mtg. Am. Soc. Clin. Oncol., Orlando, FL, 2002, Abstr., 1382.
45. Tan, A.R.; Headlee, D.; Messmann, R.; Sausville, E.A.; Arbuck, S.G.; Murgo, A.J.; Melillo, G.; Zhai, S.; Figg, W.D.; Swain, S.M.; Senderowicz, A.M. Phase I clinical and pharmacokinetics study of flavopiridol administered as a daily 1 hour infusion in patients with advanced neoplasms. J. Clin. Oncol., 2002, 20: 4074-4082.
46. th Annu. Mtg. Am. Soc. Clin. Oncol.,: New Orleans, LO, 2004, Abstr. 2031.
47. th Annu. Mtg. Proc. Am. Assoc. Cancer Res.,: New Orleans, LO, 2001, Abstr., 2179.
48. Pevarello, P.; Amici, R.; Villa, M.; Salom, B.; Vulpetti, A.; Varasi, M.; Brasca, M.G.; Traquandi, G.; Nesi, M. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents. PCT Pat. Apl. WO2003008365A2, July 2, 2002.
49. th Annu. Mtg. Proc. Am. Assoc. Cancer Res.,: Orlando, FL, 2004, Abstr., 826.
50. Reich, S.H.; Wallace, M.B. Pyrazoles for inhibiting protein kinase. PCT Pat. Apl. WO0179198 A1, Apr. 5, 2001.
51. Harrington, E.A.; Bebbington, D.; Moore, J.; Rasmussen, R.K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J.A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J.M.C.; Miller, K.M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med., 2004, 10, 262-267.
52. Tang, J.; Shewchuk, L.M.; Sato, H.; Hasegawa, M.; Washio, Y.; Nishigaki, N. Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and x-ray crystallographic analysis. Bioorg. Med. Chem. Lett., 2003, 13, 2985-2988.
53. Pevarello, P.; Brasca, M.G.; Amici, R.; Orsini, P.; Traquandi, G.; Corti, L.; Piutti, C.; Sansonna, P.; Villa, M.; Pierce, B.S.; Pulici, M.; Giordano, P.; Martina, K.; Fritzen, E. L.; Nugent, R.A.; Casale, E.; Cameron, A.; Ciomei, M.; Roletto, F.; Isacchi, A.; Fogliatto, G.; Pesenti, E.; Pastori, W.; Marsiglio, A.; Leach, K.L.; Clare, P.M.; Fiorentini, F.; Varasi, M.; Vulpetti, A.; Warpehoski, M.A. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J. Med. Chem., 2004, 47, 3367-3380.
54. th Annu. Mtg. Proc. Am. Assoc. Cancer Res.,: Orlando, FL, 2004, Abstr., 824.
55. th Annual Mtg. Proc. Am. Assoc. Cancer Res.,: Washington, DC, 2003, Abstr., 3975.
56. st Anglo-Swedish Medicinal Chemistry Symposium, Are, Sweden, 2003, Lecture, 2.
57. th Annu. Mtg. Proc. Am. Assoc. Cancer Res.,: San Francisco, CA, 2002, Abstr., 329.
58. th Annu. Mtg. Proc. Am. Assoc. Cancer Res.,: Orlando, FL, 2004, Abstr., 2479.
59. Yue, E.W.; Higley, C.A.; DiMeo, S.V.; Carini, D.J.; Nugiel, D.A.; Benware, C.; Benfield, P.A.; Burton, C.R.; Cox, S.; Grafstrom, R.H.; Sharp, D.M.; Sisk, L.M.; Boylan, J.F.; Muckelbauer, J.K.; Smallwood, A.M.; Chen, H.; Chang, Chong-Hwan; Steven P.; Trainor, G.L. Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3. J. Med. Chem., 2002, 45, 5233-5248.
60. th Annu. Mtg. Proc. Am. Assoc. Cancer Res., Orlando, FL, 2004, Abstr., 833.
61. Luk, K-C.; Simcox, M.E.; Schutt, A.; Rowan, K.; Thompson, T.; Chen, Y.; Kammlott, U.; DePinto, W.; Dunten, P.; Dermatakis, A. A new series of potent oxindole inhibitors of CDK2. Bioorg. Med. Chem. Lett., 2004, 14, 913-17.
62. Dermatakis A; Luk K C; DePinto W. Synthesis of potent oxindole CDK2 inhibitors. Bioorg. Med. Chem., 2003, 11, 1873-1881.
63. Ortega, S.; Malumbres, M.; Barbacid, M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta, 2002, 1602, 73-87.
64. Shapiro, G.I.; Harper, J.W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest., 1999, 104, 1645-1653.
65. Steiner, M.S.; Zhang, Y.; Farooq, F.; Lerner, J.; Wang, Y.; Lu, Y. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther., 2000, 7, 360-372.
66. Soni, R.; O'Reilly, T.; Furet, P.; Muller, L.; Stephan, C.; Zumstein-Mecker, S.; Frets, H.; Fabbro, D.; Chaudhuri, B. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J. Natl. Cancer Inst., 2001, 93, 436-446.
67. Fry, D.W.; Bedford, D.C.; Harvey, P.H.; Fritsch, A.; Keller, P.R.; Wu, Z.; Dobrusin, E.; Leopold, W.R.; Fattaey, A,; Garrett, M.D. Cell cycle and biochemical effects of PD 0183812. J. Biol. Chem., 2001, 276, 16617-16623.
68. Fry, D.W.; Harvey, P.J.; Keller, P.R.; Elliott, W.L.; Meade, M.; Trachet, E.; Albassam, M.; Zheng, X.; Leopold, W.R.; Pryer, N.K.; Toogood, P.L. Specific inhibition of Cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther., 2004, 3, 1427-1437.
69. Barvian, M.; Boschelli, D.; Cossrow, J.; Dobrusin, E.; Fattaey, A.; Fritsch, A.; Fry, D.; Harvey, P.; Keller, P.; Garrett, M.; La, F.; Leopold, W.; McNamara, D.; Quin, M.; Trumpp-Kallmeyer, S.; Toogood, P.; Wu, Z.; Zhang, E. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem., 2000, 43, 4606-4616.
70. Beattie, J.F.; Breaut, G.A.; Ellston, R.P.A.; Green, S., Jewsbury, P.J.; Midgley, C.J.; Naven, R.T.; Minshull, C.A.; Pauptit, R.A.; Tucker, J.A.; Pease, J.E. Cyclin-dependent kinase 4 inhibitors as treatment for cancer. Part 1: identification and optimization of substituted 4,6-Bis aniline pyrimidines. Bioorg. Med. Chem. Lett., 2003, 13, 2955-2960.
71. Carini, D.J.; Kaltenbach, R.F.; Liu, J.; Benfield, P.A.; Boylan, J.; Boisclair, M.; Brizuela, L.; Burton, C.R.; Cox, S.; Grafstrom, R.; Harrison, B.A.; Harrison, K.; Akamike, E.; Markwalder, J.A.; Nakano, Y.; Seitz, S.P.; Sharp, D.M.; Trainor, G.L.; Sielecki, T.M. Identification of selective inhibitors of cyclin dependent kinase 4. Bioorg. Med. Chem. Lett., 2001, 11, 2209-2211.
72. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: New de Novo Design Strategy and Library Design. J. Med. Chem., 2001, 44, 4615-4627.
73. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem., 2001, 44, 4628-4640.
74. Kubo A.; Nakagawa K.; Varma R.K.; Conrad N.K.; Cheng J.Q.; Lee W.C.; Testa J.R.; Johnson B.E.; Kaye F.J.; Kelley M.J. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclindependent kinase 4. Clin. Cancer Res., 1999, 5, 4279-4286.
75. McInnes, C.; Wang, C.; Anderson, S.; O'Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G.; Lane, D.P.; Fischer, P.M. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem. Biol., 2004, 11, 525-534.
76. Dobrusin, E.M.; Hamby, J.M.; Kramer, J.B.; Schroeder, M.C.; Showalter, H.D.H.; Toogood, P.; Trumpp-Kallmeyer, S.A. Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation. PCT Pat. Apl. WO9961444 A2, May 10, 1999.
77. Barvian, M.R.; Bathini, Y.; Dobrusin, E.M.; Kaltenbronn, J.S.; Micetich, R.G.; Sidhu, I.S.; Singh, R.; Toogood, P.L.; Winters, R.T. Quinqzolines and their use for inhibiting cyclin-dependent kinase enzymes. PCT Pat. Apl. WO2001038315 A1, Nov. 3, 2000.
78. Booth, R.J.; Dobrusin, E.M.; Josyula, V.P.; Venkata, N.; McNamara, D.J.; Toogood, P.L. Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors. PCT Pat. Apl. WO2001055147 A1, Jan. 23, 2001.
79. Denny, W.A.; Dobrusin, E.M.; Kramer, J.B.; McNamara, D.J.; Rewcastle, G.W.; Showalter, H.D.H.; Toogood, P.L. Pteridinones as kinase inhibitors. PCT Pat. Apl. WO2001019825 A1, June 21, 2000.
80. Booth, R.J.; Dobrusin, E.M.; Toogood, P.L.; Vanderwel, S.N. 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors. PCT Pat. Apl. WO2001070741 A1, Jan. 29, 2001.
81. Repine, J.T. 2-thia-1,6,8-triaza-naphthalene-2,2-dioxides as cdk inhibitors. PCT Pat. Apl. WO2003062246 A1, Jan. 13, 2003.
82. Barvian, M.R.; Booth, R.J.; Quin, J. III.; Repine, J.T.; Sheehan, D.J.; Toogood, P.L.; Vanderwel, S.N.; Zhou, H. 2-(pyridine-2-ylamino)-pyido[2,3d]pyrimidin-7-ones. PCT Pat. Apl. WO2003062236 A1, Jan. 10, 2003.
83. Breault, G.A.; Ellston, R.P.A.; Green, S.; James, S.R.; Jewsbury, P.J.; Midgley, C.J.; Pauptit, R.A.; Minshull, C.A.; Tucker, J.A.; Pease, J.E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimization of substituted 2,4-bis anilino pyrimidines. Bioorg. Med. Chem. Lett., 2003, 13, 2961-2966.
84. Beattie, J.F.; Breault, G.A.; Ellston, R.P.A.; Green, S.; Jewsbury, P.J.; Midgley, C.J.; Naven, R.T.; Minshull, C.A.; Pauptit, R.A.; Tucker, J.A.; Pease, J.E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimization of substituted 4,6-Bis anilino pyrimidines. Bioorg. Med. Chem. Lett.,2003, 13, 2955-2960.
85. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayama, T. & Nishimura, S. Crystallographic approach to identification of cyclin-dependent 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem., 2001, 276, 27548-27554.
86. Hayama, T.; Hayashi, K.; Honma, M.; Takahashi, I. Biarylurea derivatives. PCT Pat. Apl. WO2001007411 A1, July 26, 2000.
87. Chen, L.; Ding, Q.; Gillespie, P.; Kim, K.; Lovey, A.J.; McComas, W. W.; Mullin, J. G. Jr.; Perrotta, A. Diaminothiazoles. PCT Pat. Apl. WO2002057261 A1, Jan. 18, 2002.
88. Chu, X.; Ding, Q.; Jiang, N.; Kim, K.; Lovey, A.J.; McComas, W.W.; Mullin, J.G. Jr.; Tilley, J.W. Diaminothiazoles. PCT Pat. Apl. WO2003097048 A1, May 12, 2003.
89. Chong, W.K.M.; Chu, S.S.; Duvadie, R.R.; Li, L.; Xiao, W.; Yang, Y. 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases. PCT Pat. Apl. WO9921845 A2, Oct. 27, 1998.
90. Sanchez-Martinez, C.; Shih, C.; Zhu, G.; Li, T.; Brooks, H.B.; Patel, B.K.R.; Schultz, R.M.; DeHahn, T.B.; Spencer, C.D.; Watkins, S.A.; Ogg, C.A.; Considine, E.; Dempsey, J.A.; Zhang, F. Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides. Bioorg. Med. Chem. Lett., 2003, 13, 3841-3846.
91. Dickerson, S.H.; Drewry, D.H. Oxindole derivatives. PCT Pat. Apl. WO0220524. A1, June 28, 2001.
92. th Annu. Mtg. Proc. Am. Assoc. Cancer Res., San Francisco, CA, 2002, Abstr., 1611.
93. Rane, S.G.; Dubus, P.; Mettus, R.V.; Galbreath, E.J.; Boden, G.; Reddy, E.P.; Barbacid, M. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat. Genet., 1999, 22, 44-52.
94. Tsutsui, T.; Hesabi, B.; Moons, D.S.; Pandolfi, P.P.; Hansel, K.S.; Koff, A.; Kiyokawa, H. Targeted disruption of Cdk4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol. Cell. Biol., 1999, 19, 7011-7019.
95. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J.L.; Malumbres, M.; Barbacid, M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet., 2003, 35, 25-31.
96. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite Cdk2 inhibition. Cancer Cell, 2003, 3, 233-245.
97. th Annu. Mtg. Am. Soc. Clin. Oncol., Chicago, IL, 2003, Abstr., 835.
98. th Annu. Mtg. Proc. Am. Soc. Clin. Oncol. Chicago, IL, 2003, Abstr., 798.
99. th Annu. Mtg. Proc. Am. Soc. Clin. Oncol., Chicago, IL, 2003, Abstr. 799.
100. Kawabe, S.; Roth, J.A.; Wilson, D.R.; Meyn, R.E. Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung carcinoma cells in a p53 dependent manner. Oncogene, 2000, 19, 5359-5366.
101. Plath, T.; Peters, M.; Detjen, K.; Welzel, M.; von Marschall, Z.; Radke, C.; Wiedenmann, B.; Rosewicz, S. Overexpression of pRb in human pancreatic carcinoma cells: Function in chemotherapy-induced apoptosis. J. Natl. Cancer Inst., 2002, 94, 129-141.
102. Fukuoka, K.; Nishio, K.; Fukumoto, H.; Arioka, H.; Kurokawa, H.; Ishida, T.; Iwamoto, Y.; Tomonari, A.; Suzuki, T.; Usuda, J.; Narita, N.; Saijo, N. Ectopic p16INK4a expression enhances CPT-11 induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. Int. J. Cancer, 2000, 86, 197-203.
103. Schmitt, C.A.; Fridman, J.S.; Yang, M.; Lee, S.; Baranov, E.; Hoffman, R.M.; Lowe, S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell, 2002, 109, 335-346.
104. Davis, S. T; Benson, B.G.; Bramson, H.N.; Chapman, D.E.; Dickerson, S.H.; Dold, K.M.; Eberwein, D.J.; Edelstein, M.; Frye, S.V.; Gampe, R.T. Jr.; Griffin, R.J.; Harris, P.A.; Hassel, A.M.; Holmes, W.D.; Hunter, R.N.; Knick, V.B.; Lackey, K.; Lovejoy, B.; Luzzion, M.J.; Murray, D.; Parker, P.; Rocque, W.J.; Shewchuk, L.; Veal, J.M.; Walker, D.H.; Kuyper, L.F. Prevention of chemotherapy-induced alopecia in rats by Cdk inhibitors. Science, 2001, 291, 134-137.
105. Vassielev, L.T.; Tovar, C.; Chen, S.; Knezevic, D.; Zhao, X.; Sun, H.; Heimbrook, D.C.; Chen, Li. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. USA, 2006, 103, 10660-10665.
106. Chen, S.; Chen, L.; Le, N.L.; Zhao, C.; Sidduri, A.; Lou, J.P.; Michoud, C.; Portland, L.; Jackson, N.; Liu, J-J.; Konzelmann, F.; Chi, F.; Tovar, C.; Xiang, Q.; Chen, Y.; Wen, Y.; Vassilev, L.T. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors Bioorg. Med. Chem. Lett., 2007, 17, 2134-2138.
107. Marzec, M.; Kasprzycka, M.; Lai, R.; Gladden, A.B.; Wlodarski, P.; Tomczak, E.; Nowell, P.; DePrimo, S.; Sadis, S.; Eck, S.; Schuster, S.J.; Diehl, J.A.; Wasik, M.A. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood, 2006, 108, 1744-1750.
108. Baughn, L.B.; Libetro, M.D.; Wu, K.; Toogood, P.L.; Louie, T.; Gottschalk, R.; Niesvizky, R.; Cho, H.; Ely, S.; Moore, M.A.S.; Chen-Kiang, S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res., 2006, 66, 7661-7667.
109. Menu, E.; Garcia, J.; Huang, X.; Liberto, M.D.; Toogood, P.L.; Chen, I.; Vaanderkerken, K.; Chen-Kiang, S. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res., 2008, 68, 5519-5523.
110. Shimamura, T., Shibata, J., Kurihara, H., Mita, T., Otsuki, S., Sagara, T., Hirai, H., Iwasawa, Y. Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4,6 inhibitors with significant selectivity over CDK1, 2, 5, 7 and 9. Bioorg. Med. Chem. Lett., 2006, 16, 3751-3754.
111. Sekine, C.; Sugihara, T.; Miyake, S.; Hirai, H.; Yoshida, M.; Miyasaka, N.; Kohsaka, H. Successful treatment of animal models of rheumatoid arthritis with small-molecular cyclin-dependent kinase inhibitors. J. Immunol., 2008, 180, 1954-1961.
112. Tsou, H-R., Otteng, M. Tran, T., Floyd Jr., M.B., Reich, M., Birnberg, G., Kutterer, K., Ayral-Kaloustian, S., Ravi, M., Nilakantan, R., Grillo, M., McGinnis, J. P., Rabindran, A.K. 4-(phenylaminomethylene) isoquinoline-1,3(2H,4H)-diones as Potent and Selective Inhibitors of the Cyclin-Dependent Kinase 4 (CDK4). J. Med. Chem., 2008, 51, 3507-3525.
113. Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Sivakumar, M.; Mascarenhas, M.; Kamble, S.; Lal, B.; Sharma, S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol. Cancer Ther., 2007, 6, 918-925.
114. Joshi, K.S.; Rathos, M.J.; Joshi, R.D.; Mahajan, P.; Wagh, V.; Shenoy, S.; Bhatia, D.; Chile, S.; Sivakumar, M.; Maier, A.; Fiebig, H.; Sharma, S. P276-00, a novel cyclin-dependent kinase inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol. Cancer Ther., 2007 6, 926-934.
115. Marchetti, F.; Sayle, K.L.; Bentley, J.; Clegg, W.; Curtin, N.J.; Endicott, J.A.; Golding, B.T.; Griffin, R.J.; Haggerty, K.; Harrington, R.W.; Mesguiche, V.; Newell, D.R.; Noble, M.E.M.; Parsons, R.J.; Pratt, D.J.; Wang, L.Z.; Hardcastle, I.R. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Org. Biomol. Chem., 2007, 5, 1577-1585
116. Davis, T.G.; Bentley, J.; Arris, C.E.; Boyle, F.T.; Curtin, N.J.; Endicott, J.A.; Gibson, A.E.; Golding, B.T.; Griffin, R.J.; Hardcastle, I.R.; Jewsbury, P.; Johnson, L.N.; Mesguiche, V.; Newell, D.R.; Noble, M.E.M.; Tucker, J.A.; Wang, L.; Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol., 2002, 9, 745-749